Gilead Sciences (NASDAQ:GILD) CEO Sells $1,447,900.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the sale, the chief executive officer directly owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Thursday, February 5th, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00.
• On Wednesday, January 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00.
• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The shares were sold at an average price of $135.00, for a total value of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $1.08 during trading on Monday, reaching $150.03. 7,088,060 shares of the stock traded hands, compared to its average volume of 7,777,908. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The stock has a market capitalization of $186.25 billion, a P/E ratio of 22.16, a price-to-earnings-growth ratio of 1.95 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a 50-day moving average of $136.10 and a 200-day moving average of $124.84.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s payout ratio is 48.45%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GILD shares. Oppenheimer increased their target price on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. TD Cowen lifted their target price on Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. Argus increased their price target on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, UBS Group increased their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Twenty-three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $156.72.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter worth $26,000. Wealth Preservation Advisors LLC boosted its position in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $28,000. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.